Lessons Learned About Antibodies

The term “antibody” has entered our main-stream vocabulary due to the advent of SARS-CoV-2 with manifestation of disease as COVID-19.

Antibodies are also called immunoglobulins. They are protein/carbohydrate structures of five different classes produced in defensive response to a foreign invader. Each class binds to alien structures responsible for inducing a host reaction.

The basic unit for each antibody class incorporates a constant portion, a structural part that does not change, and another region that is variable. This variable region enables antibodies’ abilities to recognize and attach to various foreign invaders, or antigens. Over a lifetime, each human encounters many types of antigens ranging from allergens, to toxins, to various microorganisms including viruses.

Humans produce white blood cells called B-cells, which mature into plasma cells that produce five classes of immunoglobulins. Antibodies may interfere with infection through virus specific methods of neutralization. Examples include blocking virus attachment to the host cell, preventing viruses from entering the cell, clumping of multiple virus particles, disrupting reformation of virus particles, and others.

Antibodies are grouped into two primary types, termed monoclonal or polyclonal, thusly differentiated by methods through which they are produced. Polyclonal antibodies are generated in living animals from multiple B-cells thus the antibodies are heterogeneous in nature. They identify and react to various sites or epitopes on the antigens. 

Conversely, monoclonal antibodies are created artificially and propagated in tissue culture systems.  They are derived from identical B-cells called clones, which originated from a single parent cell. Therefore, monoclonal antibodies possess an ability to recognize the same epitope on an antigen and specifically bind to that one site.

The process to produce monoclonal antibodies starts with an injection of the desired antigen into a test-subject (usually a mouse), with repeated antigen injections, encouraging an immune reaction. Once the animal develops a response to the antigen, B-cells are isolated from the test subject’s spleen and fused with myeloma cells, creating immortalized B-cell-myeloma hybridomas.

These hybridoma cells possess the ability to grow continuously in tissue culture while producing antibodies. Next, the cells in culture are screened for production of the desired monoclonal antibody, which binds with the antigen of interest in the desired region. Positive characteristics for monoclonal antibodies include their high specificity for a single epitope which results in low cross-reactivity, and commercial production of large quantities resulting in highly homogeneous products.

Drawbacks for monoclonal antibody generation include a lengthy time frame for production, and high cost associated with their development.

Regeneron developed two monoclonal antibodies; each one attaches to a different epitope of the receptor binding domain of the SARS-CoV-2 spike protein. The virus spike protein confers binding ability with subsequent integration into host cells via the ACE2 receptor.

In phase II/III testing, a cocktail of the two monoclonals seems to neutralize the virus’s ability to bind, thus decreasing infection. In addition, the monoclonals do not seem to impair normal enzyme binding with resultant cell function for the ACE2 receptor. It is hoped this monoclonal cocktail may prove useful for people with COVID-19 and as prophylactic treatment for SARS-CoV-2 infection.

Programming Note:

Listen to Julia Brodt report this story live during Talk Ten Tuesdays today at 10 a.m. EST.

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn
Email
Print

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Revolutionize Case Management and Revenue Cycle Team Collaboration to Improve Patient and Financial Outcomes

Revolutionize Case Management and Revenue Cycle Team Collaboration to Improve Patient and Financial Outcomes

Unlock the keys to bridging the clinical-finance disconnect by transforming your approach to revenue cycle collaboration for superior patient care and financial prosperity!

Join Dr. Ronald Hirsch as he delves into the pivotal connection between case management, utilization review, and hospital revenue cycles, unveiling strategies to enhance communication and align goals effectively. Discover how to overcome hidden challenges hindering seamless collaboration and gain insights imperative for success

Print Friendly, PDF & Email
December 7, 2023
Mastering the Two-Midnight Rule: Keys to Navigating Short-Stay Admissions with Confidence

Mastering the Two-Midnight Rule: Keys to Navigating Short-Stay Admissions with Confidence

The CMS Two-Midnight Rule and short-stay audits are here to stay, impacting inpatient and outpatient admissions, ASC procedures, and Medicare Parts C & D. New for 2024, the Two-Midnight Rule applies to Medicare Advantage patients, requiring differentiation between Medicare plans affecting Case Managers, Utilization Review, and operational processes and knowledge of a vital distinction between these patients that influences post-discharge medical reviews and compliance risk. Join Michael G. Calahan for a comprehensive webcast covering federal laws for all admission processes. Gain the knowledge needed to navigate audits effectively and optimize patient access points, personnel, and compliance strategies. Learn Two-Midnight Rule essentials, Medicare Advantage implications, and compliance best practices. Discover operational insights for short-stay admissions, outpatient observation, and the ever-changing Inpatient-Only Listing.

Print Friendly, PDF & Email
September 19, 2023
Unlocking Clinical Documentation Excellence: Empowering CDISs & Coders

Unlocking Clinical Documentation Excellence: How to Engage the Provider

Uncover effective techniques to foster provider understanding of CDI, empower CDISs and coders to customize their queries for enhanced effectiveness, and learn to engage adult learners, leveraging their experiences for superior learning outcomes. Elevate your CDI expertise, leading to fewer coding errors, reduced claim denials, and minimized audit issues.

Print Friendly, PDF & Email
December 14, 2023
Coding for Spinal Procedures: A 2-Part Webcast Series

Coding for Spinal Procedures: A 2-Part Webcast Series

This exclusive ICD10monitor webcast series will help you acquire the critical knowledge you need to completely and accurately assign ICD-10-PCS and CPT® codes for spinal fusion and other common spinal procedures.

Print Friendly, PDF & Email
October 26, 2023
Inpatient Spinal Fusions: Mastering Anatomy, Coding and Documentation

Inpatient Spinal Fusions: Mastering Anatomy, Coding and Documentation

During this exclusive ICD10monitor webcast, inpatient coders will gain a profound understanding of prevalent spinal procedures. They’ll delve into the intricate anatomy, grasp the purpose and method behind these procedures, uncover essential elements within physician documentation, and receive expert guidance, step by step, on constructing accurate ICD-10-PCS codes. It’s the key to enhancing their expertise and ensuring coding precision.

Print Friendly, PDF & Email
October 26, 2023

Trending News